Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

被引：0
|
作者：
Passaro, A. [1 ]
Wang, J. [2 ]
Shah, S. [3 ]
Bauml, J. M. [3 ]
Campelo, R. G. [4 ]
Cho, B. C. [5 ]
机构：
[1] IRCCS, European Inst Oncol, Div Thorac Oncol, Milan, Italy
[2] Chinese Acad Med Sci & Peking Union Med Coll, Beijing, Peoples R China
[3] Janssen Res & Dev, Spring House, PA USA
[4] Univ Hosp A Coruna, La Coruna, Spain
[5] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷 / 03期
关键词：
VENOUS THROMBOEMBOLISM; RISK; CANCER;
D O I：
10.1016/j.annonc.2023.11.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：328 / 329
页数：2
相关论文
共 50 条
  • [1] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Passaro, A.
    Wang, J.
    Wang, Y.
    Lee, S. -H.
    Melosky, B.
    Shih, J. -Y.
    Wang, J.
    Azuma, K.
    Juan-Vidal, O.
    Cobo, M.
    Felip, E.
    Girard, N.
    Cortot, A. B.
    Califano, R.
    Cappuzzo, F.
    Owen, S.
    Popat, S.
    Tan, J. -l.
    Salinas, J.
    Tomasini, P.
    Gentzler, R. D.
    William, W. N.
    Reckamp, K. L.
    Takahashi, T.
    Ganguly, S.
    Kowalski, D. M.
    Bearz, A.
    MacKean, M.
    Barala, P.
    Bourla, A. B.
    Girvin, A.
    Greger, J.
    Millington, D.
    Withelder, M.
    Xie, J.
    Sun, T.
    Shah, S.
    Diorio, B.
    Knoblauch, R. E.
    Bauml, J. M.
    Campelo, R. G.
    Cho, B. C.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (01) : 77 - 90
  • [2] Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
    Moik, F.
    Riedl, J. M.
    Ay, C.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (03) : 327 - 327
  • [3] Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
    Passaro, A.
    Cho, B. C.
    Wang, Y.
    Melosky, B.
    Califano, R.
    Lee, S-H.
    Girard, N.
    Reckamp, K. L.
    Takahashi, T.
    Felip, E.
    Gentzler, R. D.
    Popat, S.
    William, W. Nassib, Jr.
    Sun, T.
    Shah, S.
    Diorio, B.
    Knoblauch, R. E.
    Bauml, J. M.
    Garcia-Campelo, M. R.
    Wang, J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1307 - S1307
  • [4] Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis
    Shih, J-Y.
    Wang, J.
    Wang, Y.
    Wang, J.
    Lee, S-H.
    Azuma, K.
    Takahashi, T.
    Tan, J-L.
    Lin, C. C.
    Ganguly, S.
    Lee, V. H. F.
    Chu, P-L.
    Shah, S.
    Diorio, B.
    Bauml, J. M.
    Cho, B. C.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1661 - S1662
  • [5] MARIPOSA-2: Randomized phase III study of amivantamab plus lazertinib plus chemotherapy vs chemotherapy alone in EGFRmutant NSCLC after osimertinib failure
    Wang, J.
    Garcia Campelo, R.
    Girard, N.
    Leighl, N.
    Reckamp, K.
    Takahashi, T.
    Li, S.
    Millington, D.
    Barala, P.
    Bauml, J. M.
    Knoblauch, R. E.
    Cho, B. C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1597 - S1597
  • [6] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
    Shreeve, S. M.
    Martinez, M.
    Verheijen, R. B.
    Xie, J.
    Sun, T.
    Haddish-Berhane, N.
    Curtin, J. C.
    Karkera, J.
    Pang, D.
    Roshak, A.
    Knoblauch, R. E.
    Patel, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
  • [7] Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
    Leighl, N. B.
    Shu, C. A.
    Minchom, A.
    Felip, E.
    Cousin, S.
    Cho, B. C.
    Park, K.
    Han, J-Y.
    Boyer, M.
    Lee, C. K.
    Moreno Garcia, V.
    Tomasini, P.
    Viteri, S.
    Xie, J.
    Mertz, J.
    Artis, E.
    Schnepp, R. W.
    Knoblauch, R. E.
    Thayu, M.
    Trigo Perez, J. M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S951 - S952
  • [8] MARIPOSA: phase 3 study of first-line amivantamab plus lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer
    Cho, Byoung Chul
    Felip, Enriqueta
    Hayashi, Hidetoshi
    Thomas, Michael
    Lu, Shun
    Besse, Benjamin
    Sun, Tao
    Martinez, Melissa
    Sethi, Seema N.
    Shreeve, S. Martin
    Spira, Alexander, I
    [J]. FUTURE ONCOLOGY, 2022, 18 (06) : 639 - 647
  • [9] Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
    Shu, Catherine A.
    Goto, Koichi
    Ohe, Yuichiro
    Besse, Benjamin
    Lee, Se-Hoon
    Wang, Yongsheng
    Griesinger, Frank
    Yang, James Chih-Hsin
    Felip, Enriqueta
    Sanborn, Rachel E.
    Caro, Reyes Bernabe
    Curtin, Joshua C.
    Chen, Jun
    Mahoney, Janine M.
    Trani, Leonardo
    Bauml, Joshua Michael
    Knoblauch, Roland Elmar
    Thayu, Meena
    Cho, Byoung Chul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study
    Felip, Enriqueta
    Cho, Byoung Chul
    Gutierrez, Vanesa
    Alip, Adlinda
    Besse, Benjamin
    Lu, Shun
    Spira, Alexander I.
    Girard, Nicolas
    Califano, Raffaele
    Gadgeel, Shirish M.
    Yang, James Chih-Hsin
    Nogami, Naoyuki
    Azuma, Koichi
    Curtin, Joshua C.
    Zhang, Jiarui
    Panchal, Anesh
    Ennis, Mariah
    Sethi, Seema Niphadkar
    Bauml, Joshua Michael
    Lee, Se-Hoon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345